
About Us
Lieva is an AI-driven health technology company developing innovative hardware and software solutions for hematology diagnostics and laboratory workflows.
Founded in 2019, Lieva began its R&D journey with projects supported by the TÜBİTAK 1512 Individual Young Entrepreneurship (BİGG) Program, establishing its technological foundation through the development of an automated blood staining device and blood analysis software. Today, Lieva continues to advance healthcare technologies by bringing together multidisciplinary expertise in biomedical engineering, software development, artificial intelligence, electronics, and mechanical design.
Lieva's core focus is the development of laboratory technologies used in the diagnosis and evaluation of hematological diseases. Our R&D and product development activities cover automated blood staining systems, digital peripheral blood smear scanning technologies, AI-powered cell morphology analysis, blood test data interpretation, and flow cytometry reporting software.
At the heart of our technology development approach is the integration of laboratory data into a unified analytical platform. By combining complete blood count (CBC) and biochemistry results, microscopic cell images, and flow cytometry data, we develop AI-powered solutions designed to support healthcare professionals in diagnostic and clinical decision-making processes. Through this integrated approach, we aim to enable comprehensive interpretation of data from different analytical instruments and methods, improve laboratory workflow efficiency, and provide more meaningful insights for clinical decision-making.
We shape our product development processes around the needs of healthcare professionals and the practical requirements of clinical laboratories. Through collaborations with hematologists, clinicians, laboratory specialists, and academic researchers, we continuously refine our technologies by integrating real-world experience, scientific research, and clinical requirements.
Supported by national R&D funding programs, academic partnerships, and the confidence of our investors, we continuously strengthen our technological capabilities. Our multidisciplinary expertise, spanning hardware design, embedded systems, image processing, machine learning, and clinical software development, enables us to focus on transforming research outcomes into practical healthcare technologies.
Our vision is to transform diverse hematology analysis technologies into integrated, accessible, and reliable systems that support healthcare professionals, while developing competitive health technologies for international markets.
Amet minim mollit non deserunt ullamco est sit aliqua fdg do amet sint.
Yatırımcı İlişkileri
Lösemi, Lenfoma gibi kan kanserlerinin ve diğer kan hastalıklarının tanı sürecini kolaylaştırmak için 3 farklı tıbbı veriyi tek platformda bir araya getirerek yapay zeka ile analiz ediyoruz ve hastalar hakkında çıkarımlar oluşturuyoruz. Lösemi, Lenfoma gibi kan kanserlerinin ve diğer kan hastalıklarının tanı sürecini kolaylaştırmak için 3 farklı tıbbı veriyi tek platformda bir araya getirerek yapay zeka ile analiz ediyoruz ve hastalar hakkında çıkarımlar oluşturuyoruz.Lösemi, Lenfoma gibi kan kanserlerinin ve diğer kan hastalıklarının tanı sürecini kolaylaştırmak için 3 farklı tıbbı veriyi tek platformda bir araya getirerek yapay zeka ile analiz ediyoruz ve hastalar hakkında çıkarımlar oluşturuyoruz.





